close Video Fox News Flash top headlines for June 20 Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com.
Join Fox News for access to this content Plus special access to select articles and other premium content with your account - free of charge. By entering your email and pushing continue, you are agreeing to Fox News' Terms of Use and Privacy Policy , which includes our Notice of Financial Incentive . Please enter a valid email address.
By entering your email and pushing continue, you are agreeing to Fox News' Terms of Use and Privacy Policy , which includes our Notice of Financial Incentive . Having trouble? Click here. A new drug to control liver disease has gotten the green light.
The U.S. Food and Drug Administration (FDA) has approved the French drugmaker Ipsen’s medication Iqirvo (elafibranor).
The drug, an 80 mg tablet administered orally once daily, is intended to treat an autoimmune cholestatic liver disease called primary biliary cholangitis (PBC). What is PBC? PBC is a disease in which the immune system attacks and destroys the small bile ducts of the liver. IN ALZHEIMER’S BREAKTHROUGH, RESEARCHERS IDENTIFY ‘PROTECTIVE GENE’ THAT DELAYS DISEASE IN HIGH-RISK FAMILY Without the active bile ducts, acids can then leak into the nearby tissue and cause liver damage or failure, according to the National Institutes of Health (NIH).
The U.S. Food and Drug Administration (FDA) has approved the French drugmaker Ipsen’s medication Iqirv.
